Piper Jaffray analyst Edward Tenthoff said he views Sanofi's (SNY) decision not to opt-in for global rights on lumasiran for the treatment of Primary Hyperoxaluria Type 1, or PH1, as a positive for Alnylam (ALNY), as he believes lumasiran could represent a fourth RNAi therapy with potential approval by 2020. Tenthoff, who said he is confident in FDA approval of patisiran by the August 11 PDUFA date and expects givosiran approval in 2019, keeps an Overweight rating and $182 target on Alnylam shares.

After IGM Biosciences (IGMS) announced that the company's exclusive worldwide collaboration agreement with Sanofi (SNY) to create and develop IgM agonist antibodies will now focus exclusively on immunology and inflammation targets, Stifel analyst Stephen Willey said the firm believes the re-focusing of the collaboration away from oncology and exclusively to the three, yet-to-be-disclosed IAI targets "removes some longer-term economic optionality," but ultimately doesn't change the firm's thesis on the stock. The firm, which adds that Sanofi's decision aligns with its continued prioritization of IAI development opportunities and doesn't reflect anything aplitabart-related and notes that IGM now regains full control of these oncology programs and could potentially re-monetize these assets via future partnerships, would be buyers on related weakness. Stifel has a Buy rating and $25 price target on IGM Biosciences shares.